Regonat (Regorafenib) 40 mg Tablets (Pack of 28/84)
Regonat is an oral multi-kinase inhibitor. Active ingredient: Regorafenib (40 mg).
Manufacturer: Natco Pharma (India). Generic equivalent of Stivarga.
The "Salvage Therapy":
Regonat is designed to block several enzymes that promote cancer growth and blood vessel formation (angiogenesis). It is typically used as a third-line or fourth-line treatment when standard therapies have failed.
✅ Benefit: Offers a treatment option for advanced cancers that are refractory to standard chemotherapy.
Indicated for the treatment of patients with:
- Metastatic Colorectal Cancer (CRC): Who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
- Gastrointestinal Stromal Tumors (GIST): Unresectable or metastatic, after failure of Imatinib and Sunitinib.
- Hepatocellular Carcinoma (HCC): For patients previously treated with Sorafenib.
Strength: 40 mg per tablet.
Standard Dosage: 160 mg (4 tablets) taken once daily.
Treatment Cycle:
- 📅 3 weeks ON (21 days).
- 📅 1 week OFF (7 days).
⚠️ IMPORTANT FOOD INSTRUCTION:
Take Regonat after a low-fat meal (less than 30% fat).
Examples: Cereal, toast, or low-fat yogurt. Avoid high-fat meals as they increase toxicity, but do not take on an empty stomach.
Storage Warning: Highly moisture sensitive. Keep tablets in the bottle with the desiccant. Once opened, use within 7 weeks.
- Severe hepatic impairment (Liver failure).
- Active bleeding or recent hemorrhage.
- Pregnancy and breastfeeding.
- Recent or planned major surgery (impairs wound healing).
Common adverse reactions include:
- Hand-Foot Skin Reaction (HFSR): Redness, pain, and peeling of palms and soles.
- Dysphonia: Hoarseness or voice changes.
- Fatigue and Hypertension.
- Diarrhea and hepatotoxicity (liver enzyme monitoring is required).
Pack size
What Customers Say
No reviews yet
Your review can be the first!